Suppr超能文献

经静脉给药后,Chol-DsiRNA 复合物替代 Chol-siRNA 可大大延长 PLL(30)-PEG(5K) 多聚物复合物在原发性鼠同源乳腺肿瘤中对 mRNA 抑制的持续时间。

Complexation of Chol-DsiRNA in place of Chol-siRNA greatly increases the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) in primary murine syngeneic breast tumors after i.v. administration.

机构信息

Lupin Ltd, 46/47, A, Village Nande, Taluka Mulshi Dist, Pune 412 115, India(1).

INSYS Therapeutics, 444 S Ellis St and 410 S Benson Ln, Chandler, AZ 85224, USA(1).

出版信息

Int J Pharm. 2018 May 30;543(1-2):130-138. doi: 10.1016/j.ijpharm.2018.03.045. Epub 2018 Mar 27.

Abstract

RNA interference has tremendous potential for cancer therapy but is limited by the insufficient potency of RNAi molecules after i.v. administration. We previously found that complexation with PLL(30)-PEG(5K) greatly increases the potency of 3'-cholesterol-modified siRNA [Chol-siRNA] in primary murine syngeneic 4T1 breast tumors after i.v. administration but mRNA suppression decreases 24 h after the final dose. We hypothesized that complexation of cholesterol-modified Dicer-substrate siRNA (Chol-DsiRNA) in place of Chol-siRNA can increase the potency and duration of suppression by polyplexes of PLL(30)-PEG(5K) in solid tumors. We found that replacing Chol-siRNA with Chol-DsiRNA increased polyplex loading and nuclease protection, suppressed stably expressed luciferase to the same extent in primary murine 4T1-Luc breast tumors under the current dosage regimen, but maintained suppression ~72 h after the final dose. The kinetics of suppression in 4T1-Luc over 72 h, however, were similar between DsiLuc and siLuc after electroporation and between polyplexes of Chol-DsiLuc and Chol-siLuc after transfection, suggesting that Chol-DsiRNA polyplexes increase the duration of mRNA suppression through differences in polyplex activities in vivo. Thus, replacing Chol-siRNA with Chol-DsiRNA may significantly increase the duration of mRNA suppression by polyplexes of PLL(30)-PEG(5K) and possibly other PEGylated polycationic polymers in primary tumors and metastases after i.v. administration.

摘要

RNA 干扰在癌症治疗方面具有巨大的潜力,但由于静脉注射后 RNAi 分子的效力不足而受到限制。我们之前发现,用 PLL(30)-PEG(5K) 进行复合可大大提高静脉注射后 3'-胆固醇修饰的 siRNA [Chol-siRNA] 在原发性小鼠同基因 4T1 乳腺肿瘤中的效力,但 mRNA 抑制在最后一次给药后 24 小时下降。我们假设用胆固醇修饰的 Dicer 底物 siRNA (Chol-DsiRNA) 代替 Chol-siRNA 进行复合,可以通过 PLL(30)-PEG(5K) 的多聚物增加实体瘤中抑制的效力和持续时间。我们发现,用 Chol-DsiRNA 代替 Chol-siRNA 可以增加多聚物的负载和核酸酶保护,在当前剂量方案下,在原发性小鼠 4T1-Luc 乳腺肿瘤中稳定表达的荧光素酶抑制到相同程度,但在最后一次给药后仍能维持抑制作用~72 小时。然而,在电穿孔后,DsiLuc 和 siLuc 之间以及 Chol-DsiLuc 和 Chol-siLuc 多聚物之间,4T1-Luc 超过 72 小时的抑制动力学相似,这表明 Chol-DsiRNA 多聚物通过体内多聚物活性的差异增加了 mRNA 抑制的持续时间。因此,用 Chol-DsiRNA 代替 Chol-siRNA 可能会显著增加 PLL(30)-PEG(5K) 多聚物和可能其他经 PEG 化的聚阳离子聚合物在原发性肿瘤和转移瘤中的 mRNA 抑制持续时间。

相似文献

6
Dicer-labile PEG conjugates for siRNA delivery.Dicer 敏感性 PEG 缀合物用于 siRNA 递呈。
Biomacromolecules. 2011 Dec 12;12(12):4301-10. doi: 10.1021/bm201199c. Epub 2011 Nov 21.

本文引用的文献

8
Delivery of RNA interference therapeutics using polycation-based nanoparticles.使用基于聚阳离子的纳米颗粒递送RNA干扰疗法。
Adv Drug Deliv Rev. 2009 Jul 25;61(9):710-20. doi: 10.1016/j.addr.2009.04.001. Epub 2009 Apr 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验